Ernexa Therapeutics Inc. Interest Payable, Current
Ernexa Therapeutics Inc. (ERNA) had Interest Payable, Current of $38.00 thousand as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:InterestPayableCurrent · last filed 2025-03-12
- 2024-09-30: Interest Payable, Current $38.00K.
- 2024-06-30: Interest Payable, Current $422.00K.
- 2024-03-31: Interest Payable, Current $407.00K.
- 2023-12-31: Interest Payable, Current $176.00K.
| Period end | Interest Payable, Current | Interest Payable, Current as first filed |
|---|---|---|
| 2024-09-30 | $38.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $422.00K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $407.00K 10-Q · filed 2024-05-14 | |
| 2023-12-31 | $176.00K 10-K · filed 2025-03-12 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | |
| 2021-12-31 | $0.00 10-K/A · filed 2022-07-01 | |
| 2021-09-30 | $194.59K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $179.60K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $164.78K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $150.00K 10-K/A · filed 2022-07-01 | $150.13K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |